Table of Contents The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies. Nippon India Pharma Fund is a Equity - Sectoral fund launched on 5 Jun 04. It is a fund with High risk and has given a Below is the key information for Nippon India Pharma Fund Returns up to 1 year are on Historical performance (Yearly) on absolute basis Nippon India PHARMA Fund - G
Scheme Objective
CAGR
return of 20.8% since its launch. Ranked 35 in Sectoral
category. Return for 2023 was 39.2% , 2022 was -9.9% and 2021 was 23.9% . NAV as on 27 Mar 24 ₹424.1 ↓ -0.19 (-0.05 %) Net Assets (AUM) as on 29 Feb 2024 ₹7,132 Cr. Launch Date 5 Jun 2004 Category Equity - Sectoral Rating ☆☆ Type Open Ended Fund Risk High AMC Nippon Life Asset Management Ltd. Alpha Ratio 1.41 Expense Ratio 1.97 % Sharpe Ratio 3.091 Information Ratio 0.54 Benchmark Not Available Min Investment ₹5,000 Min SIP Investment ₹100 Exit Load 0-1 Years (1%),1 Years and above(NIL) NAV Price Chart
Returns
Annual Compounded Returns
absolute basis
& more than 1 year are on CAGR (Compound Annual Growth Rate)
basis. as on 27 Mar 24 Duration Returns 1 Month -2.4% 3 Month 9.1% 6 Month 22.4% 1 Year 57.7% 3 Year 20.3% 5 Year 23.2% 10 Year 15 Year Since launch 20.8% Historical Annual Returns
Year Returns 2023 39.2% 2022 -9.9% 2021 23.9% 2020 66.4% 2019 1.7% 2018 3.6% 2017 7.6% 2016 -10.6% 2015 19.4% Growth of 10k Over Years
Date Value 28 Feb 19 ₹10,000 29 Feb 20 ₹10,475 28 Feb 21 ₹16,305 28 Feb 22 ₹18,785 28 Feb 23 ₹17,937 29 Feb 24 ₹28,902 Asset Allocation
Asset Class Value Cash 2.05% Equity 97.95% Sector Allocation
Sector Value Health Care 97.95% Top Securities Holdings / Portfolio
Holdings/Securities
Name Global Industry Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 09 | SUNPHARMADrug Manufacturers - Specialty & Generic 15% ₹1,035 Cr 6,556,349 Lupin Ltd (Healthcare)
Equity, Since 31 Aug 08 | 500257Drug Manufacturers - Specialty & Generic 8% ₹600 Cr 3,703,676
↓ -100,000 Cipla Ltd (Healthcare)
Equity, Since 31 May 08 | 500087Drug Manufacturers - General 6% ₹459 Cr 3,100,000 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Sep 20 | APOLLOHOSPMedical Care Facilities 6% ₹396 Cr 648,795 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 30 Jun 11 | DRREDDYDrug Manufacturers - Specialty & Generic 5% ₹353 Cr 550,030 Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLABDrug Manufacturers - Specialty & Generic 4% ₹314 Cr 900,808
↑ 50,000 Gland Pharma Ltd (Healthcare)
Equity, Since 30 Nov 20 | GLANDDrug Manufacturers - General 4% ₹300 Cr 1,700,000 Zydus Lifesciences Ltd (Healthcare)
Equity, Since 31 Jan 18 | 532321Drug Manufacturers - Specialty & Generic 4% ₹283 Cr 3,000,835 Abbott India Ltd (Healthcare)
Equity, Since 31 May 11 | ABBOTINDIADrug Manufacturers - General 3% ₹246 Cr 86,390
↑ 10,000 J.B. Chemicals & Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Jan 22 | JBCHEPHARMDrug Manufacturers - Specialty & Generic 3% ₹232 Cr 1,486,868
Talk to our investment specialistFund Managers
Name Since Tenure Sailesh Raj Bhan 1 Apr 05 18.93 Yr. Kinjal Desai 25 May 18 5.77 Yr. Custodians
Company Address Deutsche Bank AG Deutsche Bank AG,Kodak House, 22, D.N. Road, Registrar & Transfer Agent
KFin Technologies Ltd Address KFin Technologies Pvt. Ltd,,1D/D Extension 2, Valmiki Chowk,,Gandhi Nagar, FAX 91-40-23311968 Email mailmanager@karvy.com Administrator Companies
Company Address Nippon India Mutual Fund 9th Floor, Crescenzo, C-38 & 39,,G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400051 Auditors
Company Address Haribhakti & Co. Chartered Accountants 42, Free Press House,4th Floor,,215, Nariman Point, All Plan & Options
Fund and Plan NAV 6 Month 1 Year 3 Year 5 Year Nippon India Pharma Fund
Normal Dividend, Payout ₹107.977
↓ -0.05 21.52 % 56.49 % 21.75 % 25.76 % Nippon India Pharma Fund
Normal Dividend, Reinvestment ₹107.977
↓ -0.05 21.52 % 56.49 % 21.75 % 25.76 % Nippon India Pharma Fund
Growth ₹424.1
↓ -0.19 22.43 % 57.66 % 20.33 % 23.24 % Data as on 27 Mar 24